Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 147, Issue 11, Pages 3049-3058Publisher
WILEY
DOI: 10.1002/ijc.33122
Keywords
early breast cancer; pathological complete response; neoadjuvant chemotherapy; adjuvant chemotherapy
Categories
Ask authors/readers for more resources
Neoadjuvant chemotherapy (NACT) in early breast cancer (EBC) enablesin vivosensitivity testing and less radical surgery as compared to primary surgery and adjuvant chemotherapy (ACT). The aim of our study is to illustrate trends of systemic treatment of EBC. The study analyzed chemotherapy usage and time trends for patients with EBC treated at 104 German breast units between January 2008 and December 2017. The data were obtained through a quality-controlled benchmarking process. Altogether, 124 084 patients were included, of whom 46 279 (37.3%) received chemotherapy. For 44 765 of these cases, detailed information on systemic treatment and surgery were available. Overall use of chemotherapy declined from 42.0% in 2008 to 32.0% in 2017. During that same time, the proportion of NACT increased from 20.0% to 57.7%, irrespective of tumor subtype. The pathological complete response (pCR) rate (defined as ypT0 ypN0) at surgery after NACT increased from 15.0% to 34.2%. The results from this large cohort from the clinical routine reflect the refined indications for chemotherapy in EBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available